DPP4 inhibitors (DPP4i) have been developed for diabetic glucose control [57] and are being investigated for treatment of COVID-19 patients with pre-existing diabetic conditions (ClinicalTrails.gov identifier NCT04542213). Here, DPP4 is linked to COVID-19.